SciELO - Scientific Electronic Library Online

 
vol.90Influencia de las características urbanísticas ambientales en el nivel de actividad física de la población de 18 a 65 años del área metropolitana de Pamplona índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Española de Salud Pública

versão On-line ISSN 2173-9110versão impressa ISSN 1135-5727

Resumo

ALFAGEME ROLDAN, Fernando; BERMEJO HERNANDO, Almudena; CALVO GONZALEZ, José Luís  e  MARQUES SANCHEZ, Pilar. Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks. Rev. Esp. Salud Publica [online]. 2016, vol.90, e30001.  Epub 13-Abr-2016. ISSN 2173-9110.

Background:

The objective was to evaluate the efficiency (relation between the cost and the results in health) of the treatments in psoriasis, seeking a higher quality of economic evaluations, consistency and transparency in these studies.

Methods:

We developed a model of economic evaluation in psoriasis collecting all the many direct and indirect costs of each treatment. The effectiveness indicator used was Psoriasis Area Severity Index [PASI 75] which is generally acceptable in studies of psoriasis. The effectiveness indicator was a PASI 75. Subsequently we calculated the Incremental Cost-Effectiveness Ratio (ICER) for the period of 12 weeks and PASI 75, ordering treatments by level of effectiveness at the expense of treatment costs.

Results:

The most cost effective treatment was methotrexate (ICER -7.5) followed by acitretin (ICER 29.5). The least cost has proved effective PUVA (ICER 4,651), followed by UVB narrow band (2,886.1).

Conclusions:

When taking into account both direct and indirect costs together with efficiency, methotrexate is the most cost effective treatment.

Palavras-chave : Psoriasis; Cost-Effectiveness Analysis; Methotrexate; Adalimumab; Infliximab; Ustekinumab; Economic evaluation.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )